Dopamine D3 Receptor Mesdopetam Maintains Antidyskinesia Effects Despite Failure to Improve Parkinson Disease ON Time Marco Meglio

Published Date: 22 Jan 2026

A recent phase 2b study reveals mesdopetam's potential in reducing dyskinesia severity in Parkinson disease, despite no significant ON time improvement.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

A BRAF V600E mutation-positive intrathoracic synovial sarcoma is reported by researchers.

2.

No Survival Gain With Preoperative CRT Plus Perioperative Chemo for Gastric Cancer

3.

Innovative oncology therapeutics are being created in collaboration between Moderna and Immatics.

4.

An inoperable locally advanced NSCLC trial dubbed "Practice Changing".

5.

CDC Alerts on Dramatic Rise in Human Parvovirus B19


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot